Literature DB >> 9474529

Comparison of a direct and indirect population pharmacodynamic model: application to recombinant human erythropoietin in athletes.

F Bressolle1, M Audran, R Gareau, T N Pham, R Gomeni.   

Abstract

Basic physiologic indirect response models have been proposed to account for the pharmacodynamics of drugs that act by way of inhibition or stimulation of the production or loss of endogenous substances or mediators. In this work, these models were applied to account for the effects of recombinant human erythropoietin (rHuEpo) in man. Indeed, rHuEpo induces a delayed increase of serum soluble transferrin receptors (sTfr) and a delayed decrease in ferritin (fr) concentrations. The purpose of the present study was to compare two pharmacodynamic approaches to relate serum erythropoietin (Epo) concentrations to the effect of rHuEpo on sTfr, and fr, the "indirect effect" and the "effect compartment" models. However, due to the average lag time of about 50 hr between the first intake of rHuEpo and the onset of the measurable effects, a delay function was incorporated into the "indirect response models" to describe the relationship between the Epo plasma concentrations and the endogenous receptors or mediators affected by the drug and responsible for the effects on sTfr and fr. There are no real differences in the descriptive features of the two models used. For these reasons, the indirect model seems more appropriate because it supplies a possible mechanistic interpretation of the physiological process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9474529     DOI: 10.1023/a:1025737024403

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  11 in total

Review 1.  The molecular mechanism of erythropoietin action.

Authors:  M J Koury; M C Bondurant
Journal:  Eur J Biochem       Date:  1992-12-15

2.  Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control.

Authors:  A Souillard; M Audran; F Bressolle; R Gareau; A Duvallet; J L Chanal
Journal:  Br J Clin Pharmacol       Date:  1996-09       Impact factor: 4.335

3.  Erythropoietin abuse in athletes.

Authors:  R Gareau; M Audran; R D Baynes; C H Flowers; A Duvallet; L Senécal; G R Brisson
Journal:  Nature       Date:  1996-03-14       Impact factor: 49.962

4.  Convergence of direct and indirect pharmacodynamic response models.

Authors:  W J Jusko; H C Ko; W F Ebling
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

5.  The estimation of population pharmacokinetic parameters using an EM algorithm.

Authors:  L Aarons
Journal:  Comput Methods Programs Biomed       Date:  1993-09       Impact factor: 5.428

6.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

7.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects.

Authors:  W J Jusko; H C Ko
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

Review 8.  Peptide hormones and sport: misuse and detection.

Authors:  A T Kicman; D A Cowan
Journal:  Br Med Bull       Date:  1992-07       Impact factor: 4.291

9.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

10.  Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men.

Authors:  B Berglund; B Ekblom
Journal:  J Intern Med       Date:  1991-02       Impact factor: 8.989

View more
  3 in total

1.  Basic pharmacodynamic models for agents that alter production of natural cells.

Authors:  W Krzyzanski; R Ramakrishnan; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

Review 2.  Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control.

Authors:  Emmanuelle Varlet-Marie; Aurélie Gaudard; Michel Audran; Francoise Bressolle
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

3.  Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes : a population approach.

Authors:  A Gaudard; E Varlet-Marie; M Audran; R Gomeni; F Bressolle
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.